Similar in-person rules for other medications have been suspended during the pandemic
Euglycemic DKA ID’d in T2DM Patients With COVID-19
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS-CoV-2 infection
LY-CoV555 Not Efficacious for Hospitalized Patients With COVID-19
Enrollment stopped for futility based on no difference in pulmonary function on day 5 compared with placebo
Antibody Cocktail Enhances Clearance of SARS-CoV-2 Virus
Cocktail of two antibodies against SARS-CoV-2 spike protein reduces viral load, with greater effect in antibody-negative patients
Tocilizumab Cuts Progression to Ventilation or Death in COVID-19
But death from any cause by day 28 in those hospitalized with COVID-19 pneumonia did not differ for tocilizumab versus placebo
Adding Baricitinib Speeds Recovery for COVID-19 Pneumonia
Odds of improvement in clinical status at day 15 greater for baricitinib plus remdesivir versus remdesivir alone
Antiviral Drugs Have No Effect on Mortality in COVID-19
Remdesivir, hydroxychloroquine, lopinavir, interferon regimens have little to no effect on in-hospital mortality
Higher Doses of Z-Drugs Pose Risks for Dementia Patients
Risks for fracture, falls, ischemic stroke increased in patients with dementia prescribed higher doses of Z-drugs
AHA: Sotagliflozin Beneficial for T2DM With Heart Failure
Second study shows benefits among patients with type 2 diabetes and chronic kidney disease, risks for CVD
WHO: Remdesivir Not Advised for Hospitalized COVID-19 Patients
Evidence to date has not shown clinically important effects on mortality, need for mechanical ventilation